EVKEEZA

PeakmAb

evinacumab

BLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10

Mechanism of Action

Angiopoietin-like 3 Inhibitors

Pharmacologic Class:

Angiopoietin-like 3 Inhibitor

Clinical Trials (5)

NCT07447648N/ANot Yet Recruiting

Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

Started Mar 2026
52 enrolled
Homozygous Familial Hypercholesterolemia (HoFH)Coronary Computed Tomography Angiography
NCT05611528Phase 3Completed

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

Started Feb 2023
10 enrolled
Homozygous Familial Hypercholesterolemia
NCT04863014Phase 2Terminated

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Started Jul 2021
21 enrolled
Hypertriglyceridemia
NCT04233918Phase 3Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Started Jun 2020
20 enrolled
Homozygous Familial Hypercholesterolemia
NCT03452228Phase 2Completed

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Started Jun 2018
52 enrolled
Severe Hypertriglyceridemia (sHTG)